Researchers conducted a randomized, controlled trial in patients with the Ebola virus. Patients were divided into two groups — one was treated using the current standard of care plus ZMapp while the other was treated using only the current standard of care. The primary end point was mortality at 28 days.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
A total of 72 patients were enrolled at sites in Liberia, Sierra Leone, Guinea and the United States.
Here are four insights:
1. Of the 71 patients who could be evaluated, 21 died, representing an overall case fatality rate of 30 percent.
2. Thirteen of the 35 patients who received only the current standard of care died.
3. Eight of the 36 patients who received the current standard of care plus ZMapp died.
4. The observed posterior probability that ZMapp plus the current standard of care was superior to the current standard of care alone was 91.2 percent.This figure falls short of the prespecified threshold of 97.5 percent.
More articles on healthcare quality:
Lower heart rates reduce risk of death among septic shock patients: 4 insights
Indianapolis hospital shuts down 6 ORs to test air quality
Hospital beds’ antibiotic history can put future patients at risk for C. diff
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
